Thienamycin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Thienamycin | |
|---|---|
| Image:Thienamycinsmallish.png | |
| IUPAC name | (5R,6S)-3-[(2-Aminoethyl)thio]-6-[(1R)-1- hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid |
| Identifiers | |
| CAS number | |
| SMILES | CC(C1C2CC(=C(N2C1=O)C(=O)O)SCCN)O |
| Properties | |
| Molecular formula | C11H16N2O4S |
| Molar mass | 272.32 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references | |
|
WikiDoc Resources for Thienamycin | |
|
Articles | |
|---|---|
|
Most recent articles on Thienamycin Most cited articles on Thienamycin | |
|
Media | |
|
Powerpoint slides on Thienamycin | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Thienamycin at Clinical Trials.gov Clinical Trials on Thienamycin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Thienamycin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Thienamycin Discussion groups on Thienamycin Patient Handouts on Thienamycin Directions to Hospitals Treating Thienamycin Risk calculators and risk factors for Thienamycin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Thienamycin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Thienamycin, one of the most potent naturally-produced antibiotics known thus far, was discovered in Streptomyces cattleya in 1976. Thienamycin has excellent activity against both Gram-positive and Gram-negative bacteria and is resistant to bacterial β-lactamase enzymes.
History
In 1976, fermentation broths obtained from the soil bacteria Streptomyces cattleya were found to be active in screens for inhibitors of peptidoglycan biosynthesis[1]. Initial attempts to isolate the active species proved difficult due to the chemical instability of that component. After many attempts and extensive purification, the material was finally isolated in >90% purity, allowing for the structural elucidation of thienamycin in 1979 (Figure 1)[1].
Thienamycin was the first among the naturally-occurring class of carbapenem antibiotics to be discovered and isolated. Carbapenems are similar in structure to their antibiotic “cousins” the penicillins. Like penicillins, carbapenems contain a β-lactam ring (cyclic amide) fused to a five-membered ring. Carbapenems differ in structure from penicillins in that within the five-membered ring a sulfur is replaced by a carbon atom (C1) and an unsaturation is present between C2 and C3 in the five-membered ring.
Mechanism of Action
In vitro, thienamycin employs a similar mode of action as penicillins through disrupting the cell wall synthesis (peptidoglycan biosynthesis) of various Gram-positive and Gram-negative bacteria (Staphylococcus aureus,Staphylococcus epidermidis, Pseudomonas aeruginosa to name a few)[1]. In a study carried out by Spratt et al., they found that, although thienamycin binds to all of the penicillin-binding proteins (PBP) in Escherichia coli, it preferentially binds to PBP-1 and PBP-2, which are both associated with the elongation of the cell wall[1].
Unlike pencillins, which are rendered ineffective through rapid hydrolysis by the β-lactamase enzyme present in some strains of bacteria, thienamycin remains antimicrobially active. Neu et al. found that thienamycin displayed high activity against bacteria that were resistant to other β-lactamase stable compounds (cephalosporins), highlighting the superiority of thienamycin as an antibiotic among β-lactams[1].
Biosynthesis
The formation of thienamycin is thought to occur through a different pathway from classic β-lactams (penicillins, cephalosporins). Production of classic β-lactams in both fungi and bacteria occur through two steps: First, the condensation of L-cysteine, L-Valine, and L-α-amino adipic acid by ACV synthetase (ACVS, a nonribsomal peptide synthetase) and then cyclization of this formed tripeptide by isopenicillin N synthetase (IPNS).
The gene cluster (thn) for the biosynthesis of thienamycin by S. cattleya was identified and sequenced, finally, in 2003, lending insight into the biosynthetic mechanism for thienamycin formation[1]. Based on previous work[1] and on this significant breakthrough, a tentative biosynthetic pathway has been proposed (Figure 2).
The biosynthesis of thienamycin begins with the condensation of acetyl-S-CoA with γ-glutamyl phosphate to form the pyrroline ring. The hydroxyethyl side chain of thienamycin is thought to be a result of two separate methyl transfers from S-adenosyl methionine[1]. According to the proposed biosynthesis, one methylation step occurs immediately after formation of the pyrroline ring, and the other methylation step occurs after formation of the bicyclic ring. According to the proposed gene functions (Table 1), ThnK, ThnL, and ThnP could catalyze these methyl-transfer steps. After the first methylation step occurs, β-lactam synthetase (ThnM) is thought to catalyze the formation of the β-lactam ring fused to the five-membered ring. Incorporation of the cysteaminyl side chain is then assisted by ThnV and/or ThnT. Oxidations occur between C6 and C8, followed by the second methylation step (mentioned above), then reduction at C6 and C8, and subsequently oxidation between C2 and C3. Hydroxylation by ThnG gives thienamycin as the final product (Note: see Figure 2 for a potential alternative pathway).
Total Synthesis
Due to low titre and to difficulties in isolating and purifying thienamycin produced via fermentation, total synthesis is the preferred method for commercial production. Numerous methods are available in the literature for the total synthesis of thienamycin. One synthetic route[1] is given in Figure 3.
The starting β-lactam for the pathway given above can be synthesized via the following method (Figure 4):[1]
Clinical Use
Thienamycin itself is extremely unstable and decomposes in aqueous solution. Consequently, thienamycin is impractical for clinical treatment of bacterial infections. For this reason, stable derivatives of thienamycin were created for medicinal consumption. One such derivative, imipenem, was formulated in 1985. Imipenem, an N-formimidoyl derivative of thienamycin, is rapidly metabolized by the renal dihydropeptidase enzyme found in the human body. To prevent its rapid degradation, imipenem is normally co-administered with cilastatin, an inhibitor of this enzyme.
References
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
